5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC. - Velcheti V; Rai P; Kao YH; Chirovsky D; Nunes AT; Liu SV (Clinical lung cancer, 2024)